This protocol applies to patients with cutaneous leishmaniasis in which the causative species is Leishmania mexicana. Species identification is clinically relevant: the particular natural history of L. mexicana infection directly informs which management pathway is appropriate.
For patients meeting specific criteria around lesion characteristics and patient circumstances, a conservative approach without antileishmanial medication may be a suitable option — the complete eligibility criteria and clinical pathway are detailed in the full protocol.
Treatment goal: Complete reepithelialization of the cutaneous lesion